Lactated Ringera-s as a Base Solution for del Nido Cardioplegia

Abstract

Unavailability of Plasma-Lyte A precludes the utility of traditional del Nido cardioplegia in many countries. This observational study aimed to evaluate myocardial preservation and clinical outcomes when using lactated Ringera-s solution as the base solution for del Nido cardioplegia as compared with our institutea-s standard blood cardioplegia strategy. Eighty-nine adult patients underwent cardiac surgery for acquired heart disease from February 2017 to November 2017 either with del Nido cardioplegia (n = 44) or blood cardioplegia (n = 45). Clinical data and outcomes were compared. Patient characteristics were similar between groups. Troponin T release was lower in the del Nido group on postoperative day 1 (.632 [.437,.907] vs.827 [.599, 1.388] ng/mL; p =.009) and day 2 (.363 [.250,.451] vs.549 [.340,.897] ng/mL; p =.002). The del Nido group exhibited lower total volume of cardioplegia administered (1,075 [1,000, 1,250] vs. 3,400 [2,700, 3,750] mL; p